Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis
Summary of Results: Head-to-Head Comparisons of DMARDs
In the few head-to-head comparisons to date, disease activity and health status improve to a similar degree in both treatment arms, but the studies were not large enough and the outcome measures were too imprecise to detect any differences with statistical significance.
Keywords: anti-rheumatic | antirheumatic | biologic DMARD | D-penicillamine | disease-modifying | DMARDs | etanercept | hydroxychloroquine | infliximab | JCA | JIA | JRA | juvenile rheumatoid arthritis | leflunomide | methotrexate | non-biologic DMARD | nonbiologic DMARD | rheumatic | sulfasalazine | TNF-alpha blockers | juvenile idiopathic arthritis
- Kemper A, Coeytaux R, Sanders G, et al. Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA). Comparative Effectiveness Review No. 28 (Prepared by the Duke Evidence-based Practice Center under Contract No. HHSA 290-2007-10066-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2011. AHRQ Publication No. 11-EHC039-EF. Available at www.effectivehealthcare.ahrq.gov/dmardsjia.cfm.
Your slide tray is being processed.